Zealand Pharma A/S/ADR
ZLDPF$4.99B
Mid CapNASDAQBiotechnology🇺🇸North America
Drugs in Pipeline
4
Phase 3 Programs
3
Upcoming Catalysts
1
Next Catalyst
Apr 15, 2026
4wMarket Overview
Stock performance and key metrics
ZLDPF News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
dasiglucagon
Congenital Hyperinsulinism
Glepaglutide
Short Bowel Syndrome
GlucaGen
Hypoglycemia
Petrelintide
Overweight
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
dasiglucagon | Phase 3 | Congenital Hyperinsulinism | - | - |
Glepaglutide | Phase 3 | Short Bowel Syndrome | - | - |
GlucaGen | Phase 3 | Hypoglycemia | - | - |
Petrelintide | Phase 2 | Overweight | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply